proxyvotesnow.com

Home › Companies › ARROWHEAD PHARMACEUTICALS INC. › 2024-2025

ARROWHEAD PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ARROWHEAD PHARMACEUTICALS INC.’s Form 8-K, filed March 19, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

  • 11Reported items
  • 277Asset managers
  • 3,480Fund votes
  • March 12, 2025Meeting date

Results at a glance

Meeting of March 12, 2025: 8 items on ARROWHEAD PHARMACEUTICALS INC.’s Form 8-K, filed March 19, 2025: 8 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARROWHEAD PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ARROWHEAD PHARMACEUTICALS INC.

These tallies are ARROWHEAD PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 19, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARROWHEAD PHARMACEUTICALS INC. — official shareholder meeting results, meeting held March 12, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Christopher Anzalone 78,346,4484,406,009117,717 ---- 95%Not verified—
Elect Director: William Waddill 74,963,6847,769,128137,362 ---- 91%Not verified—
Elect Director: Michael Perry 80,137,4212,594,224138,529 ---- 97%Not verified—
Elect Director: Victoria Vakiener 80,629,5622,087,405153,207 ---- 97%Not verified—
Elect Director: Mauro Ferrari 80,079,8702,649,068141,236 ---- 97%Not verified—
Elect Director: Adeoye Olukoton 80,519,8282,219,988130,358 ---- 97%Not verified—
Elect Director: Hongbo Lu 81,171,4641,552,680146,030 ---- 98%Not verified—
Elect Director: Douglas Ingram 68,899,12413,843,071127,979 ---- 83%Not verified—

Source: ARROWHEAD PHARMACEUTICALS INC., Form 8-K, filed with the SEC on March 19, 2025 — read the filing on EDGAR.

How asset managers voted at the ARROWHEAD PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 277 asset managers that disclosed a ARROWHEAD PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARROWHEAD PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Adeoye Olukoton

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 80,519,828AGAINST: 2,219,988
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Election of Directors: Adeoye Olukotun

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Adeoye Olukoton”): 80,519,828 for, 2,219,988 against, per its Form 8-K filed March 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 36,089,979 for, 30,403 against, 34,646 abstained.

FOR
FOR: 36,089,979AGAINST: 30,403ABSTAIN: 34,646
Largest asset managers voting on “Election of Directors: Adeoye Olukotun” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street2,298,415535 00For
T. Rowe Price1,666,3500 00For
Charles Schwab1,017,7340 00For
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X218,5730 00For
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial132,0450 00For
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock124,1790 00For
Russell Investments123,9220 00For
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

2. Elect Director: Christopher Anzalone

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 78,346,448AGAINST: 4,406,009
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Election of Directors: Christopher Anzalone

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Christopher Anzalone”): 78,346,448 for, 4,406,009 against, per its Form 8-K filed March 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 36,027,394 for, 92,988 against, 34,646 abstained.

FOR
FOR: 36,027,394AGAINST: 92,988ABSTAIN: 34,646
Largest asset managers voting on “Election of Directors: Christopher Anzalone” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street2,298,615335 00For
T. Rowe Price1,666,3500 00For
Charles Schwab1,017,7340 00For
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X218,5730 00For
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial132,0450 00For
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock124,1790 00For
Russell Investments123,9220 00For
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

3. Elect Director: Douglas Ingram

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST
FOR: 68,899,124AGAINST: 13,843,071
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Election of Directors: Douglas Ingram

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Douglas Ingram”): 68,899,124 for, 13,843,071 against, per its Form 8-K filed March 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 29,920,192 for, 6,200,190 against, 34,646 abstained.

FORAGAINST
FOR: 29,920,192AGAINST: 6,200,190ABSTAIN: 34,646
Largest asset managers voting on “Election of Directors: Douglas Ingram” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street3,9642,294,986 00Against
T. Rowe Price01,666,350 00Against
Charles Schwab01,017,734 00Against
Aberdeen524,1520 00For
Equitable234,264263,794 00Mixed
TIAA306,1120 00For
Global X0218,573 00Against
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust0143,506 00Against
Lincoln Financial5,694126,351 00Against
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock116,1798,000 00Mixed
Russell Investments0123,922 00Against
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual097,780 00Against
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

4. Elect Director: Hongbo Lu

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 81,171,464AGAINST: 1,552,680
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Election of Directors: Hongbo Lu

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Hongbo Lu”): 81,171,464 for, 1,552,680 against, per its Form 8-K filed March 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 36,066,932 for, 53,450 against, 34,646 abstained.

FOR
FOR: 36,066,932AGAINST: 53,450ABSTAIN: 34,646
Largest asset managers voting on “Election of Directors: Hongbo Lu” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street2,298,415535 00For
T. Rowe Price1,666,3500 00For
Charles Schwab1,017,7340 00For
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X218,5730 00For
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial132,0450 00For
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock124,1790 00For
Russell Investments123,9220 00For
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

5. Elect Director: Mauro Ferrari

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 80,079,870AGAINST: 2,649,068
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Election of Directors: Mauro Ferrari

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mauro Ferrari”): 80,079,870 for, 2,649,068 against, per its Form 8-K filed March 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 36,001,072 for, 119,310 against, 34,646 abstained.

FOR
FOR: 36,001,072AGAINST: 119,310ABSTAIN: 34,646
Largest asset managers voting on “Election of Directors: Mauro Ferrari” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street2,298,166784 00For
T. Rowe Price1,666,3500 00For
Charles Schwab1,017,7340 00For
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X218,5730 00For
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial132,0450 00For
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock124,1790 00For
Russell Investments123,9220 00For
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

6. Elect Director: Michael Perry

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 80,137,421AGAINST: 2,594,224
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Election of Directors: Michael S. Perry

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael Perry”): 80,137,421 for, 2,594,224 against, per its Form 8-K filed March 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 36,066,683 for, 53,699 against, 34,646 abstained.

FOR
FOR: 36,066,683AGAINST: 53,699ABSTAIN: 34,646
Largest asset managers voting on “Election of Directors: Michael S. Perry” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street2,298,166784 00For
T. Rowe Price1,666,3500 00For
Charles Schwab1,017,7340 00For
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X218,5730 00For
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial132,0450 00For
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock124,1790 00For
Russell Investments123,9220 00For
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

7. Elect Director: Victoria Vakiener

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 80,629,562AGAINST: 2,087,405
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Election of Directors: Victoria Vakiener

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Victoria Vakiener”): 80,629,562 for, 2,087,405 against, per its Form 8-K filed March 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 36,051,985 for, 64,402 against, 38,641 abstained.

FOR
FOR: 36,051,985AGAINST: 64,402ABSTAIN: 38,641
Largest asset managers voting on “Election of Directors: Victoria Vakiener” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street2,298,415535 00For
T. Rowe Price1,666,3500 00For
Charles Schwab1,017,7340 00For
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X218,5730 00For
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial132,0450 00For
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock124,1790 00For
Russell Investments123,9220 00For
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

8. Elect Director: William Waddill

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 74,963,684AGAINST: 7,769,128
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Election of Directors: William Waddill

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William Waddill”): 74,963,684 for, 7,769,128 against, per its Form 8-K filed March 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 33,614,081 for, 2,506,301 against, 34,646 abstained.

FOR
FOR: 33,614,081AGAINST: 2,506,301ABSTAIN: 34,646
Largest asset managers voting on “Election of Directors: William Waddill” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street3,6782,295,272 00Against
T. Rowe Price1,666,3500 00For
Charles Schwab1,017,7340 00For
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X218,5730 00For
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial5,694126,351 00Against
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock124,1790 00For
Russell Investments123,9220 00For
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

9. Advisory vote to approve named executive officer compensation.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

94% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 269 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 70 asset managers voting on “Advisory vote to approve named executive officer compensation.” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street2,298,9500 00For
T. Rowe Price1,666,3500 00For
Charles Schwab01,017,734 00Against
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X0218,573 00Against
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan0158,209 00Against
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial126,3515,694 00For
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group0126,230 00Against
John Hancock124,1790 00For
Russell Investments0123,922 00Against
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Fund voting reports, all 70 managers: 34,165,840 for, 1,881,608 against, 34,646 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 225 asset managers voting on “Advisory vote to approve named executive officer compensation.” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Avoro Capital Advisors LLC9,936,4340 00For
State Street5,434,6690 00For
BlackRock4,808,219793 00For
Slate Path Capital LP4,644,4580 00For
Fidelity4,031,2130 00For
GEODE CAPITAL MANAGEMENT, LLC2,920,9950 00For
T. Rowe Price2,605,8050 00For
Siren, L.L.C.2,549,2190 00For
Northern Trust1,048,8750 00For
Charles Schwab01,017,778 00Against
MELLON INVESTMENTS Corp656,3310 00For
Aberdeen524,1520 00For
Vanguard460,7110 00For
UBS0351,177 00Against
Woodline Partners LP339,4410 00For
Nuveen315,9780 00For
PRINCIPAL GLOBAL INVESTORS291,8590 00For
AllianceBernstein264,6410 00For
Hound Partners, LLC262,4110 00For
BANK OF AMERICA NA0247,841 00Against
FARALLON CAPITAL MANAGEMENT LLC0219,149 00Against
SCHRODER INVESTMENT MANAGEMENT GROUP0206,070 00Against
Two Sigma199,2010 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC193,0220 00For
Russell Investments0169,159 00Against

Institutional-manager reports, all 225 managers: 44,095,193 for, 3,307,217 against, 5,380 abstained, 608 not voted. Showing the 25 largest; see all in the interactive database.

10. ADVISORY VOTE ON FREQUENCY OF EXECUTIVE COMPENSATION ADVISORY VOTES.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.9% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: votes by 268 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 70 asset managers voting on “ADVISORY VOTE ON FREQUENCY OF EXECUTIVE COMPENSATION ADVISORY VOTES.” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
BlackRock00 00--
Fidelity00 00--
State Street00 00--
T. Rowe Price00 00--
Charles Schwab00 00--
Aberdeen00 00--
Equitable00 00--
TIAA00 00--
Global X00 00--
AIG/SunAmerica00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
JPMorgan00 00--
Jackson National00 00--
Northern Trust00 00--
Lincoln Financial00 00--
Columbia Threadneedle00 00--
BUFFALO FUNDS00 00--
Capital Group00 00--
John Hancock00 00--
Russell Investments00 00--
Brighthouse00 34,6460Abstain
Northwestern Mutual00 00--
Direxion Shares ETF Trust00 00--
ProShares00 00--

Fund voting reports, all 70 managers: 34,646 abstained, 36,012,137 1 year, 35,311 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 224 asset managers voting on “ADVISORY VOTE ON FREQUENCY OF EXECUTIVE COMPENSATION ADVISORY VOTES.” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Avoro Capital Advisors LLC00 00--
State Street00 00--
BlackRock00 00--
Slate Path Capital LP00 00--
Fidelity00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
T. Rowe Price00 00--
Siren, L.L.C.00 00--
Northern Trust00 00--
Charles Schwab00 00--
MELLON INVESTMENTS Corp00 00--
Aberdeen00 00--
Vanguard00 00--
UBS00 00--
Woodline Partners LP00 00--
Rhumbline159,1130 00For
Nuveen00 00--
PRINCIPAL GLOBAL INVESTORS00 00--
AllianceBernstein00 00--
Hound Partners, LLC00 00--
BANK OF AMERICA NA00 00--
FARALLON CAPITAL MANAGEMENT LLC219,1490 00For
SCHRODER INVESTMENT MANAGEMENT GROUP00 00--
Two Sigma00 00--
PARAMETRIC PORTFOLIO ASSOCIATES LLC00 00--

Institutional-manager reports, all 224 managers: 500,637 for, 50 against, 5,380 abstained, 608 not voted, 47,231,962 1 year, 4,649 3 year. Showing the 25 largest; see all in the interactive database.

11. TO RATIFY THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER 30…

No official matchAUDIT-RELATED

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 70 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER 30, 2025.

The 70 asset managers below reported 36,047,448 for, 34,646 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 36,047,448ABSTAIN: 34,646
Largest asset managers voting on “TO RATIFY THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBE” at ARROWHEAD PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,843,0460 00For
BlackRock9,583,1640 00For
Fidelity5,184,8150 00For
State Street2,298,9500 00For
T. Rowe Price1,666,3500 00For
Charles Schwab1,017,7340 00For
Aberdeen524,1520 00For
Equitable498,0580 00For
TIAA306,1120 00For
Global X218,5730 00For
AIG/SunAmerica198,1290 00For
QUANTITATIVE MASTER SERIES LLC164,8940 00For
JPMorgan158,2090 00For
Jackson National145,2980 00For
Northern Trust143,5060 00For
Lincoln Financial132,0450 00For
Columbia Threadneedle126,5620 00For
BUFFALO FUNDS126,5100 00For
Capital Group126,2300 00For
John Hancock124,1790 00For
Russell Investments123,9220 00For
Brighthouse67,6690 34,6460Mixed
Northwestern Mutual97,7800 00For
Direxion Shares ETF Trust75,8540 00For
ProShares73,1710 00For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Largest ARROWHEAD PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 125,572,000 shares outstanding at the time of that meeting.

Fund voting reports: top ARROWHEAD PHARMACEUTICALS INC. shareholders by shares voted on “Election of Directors: Adeoye Olukotun”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 9.43%
2BlackRock 7.63%
3Fidelity 4.13%
4State Street 1.83%
5T. Rowe Price 1.33%
6Charles Schwab 0.81%
7Aberdeen 0.42%
8Equitable 0.40%
9TIAA 0.24%
10Global X 0.17%
Institutional-manager reports: top ARROWHEAD PHARMACEUTICALS INC. shareholders by shares voted on “Advisory vote to approve named executive officer compensation.”, 2024-2025
#Asset manager % of shares outstanding
1Avoro Capital Advisors LLC 7.91%
2State Street 4.33%
3BlackRock 3.83%
4Slate Path Capital LP 3.70%
5Fidelity 3.21%
6GEODE CAPITAL MANAGEMENT, LLC 2.33%
7T. Rowe Price 2.08%
8Siren, L.L.C. 2.03%
9Northern Trust 0.84%
10Charles Schwab 0.81%

Reported ARROWHEAD PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ARROWHEAD PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
BlackRock 15.87% 13F
Vanguard Group 10.51% 13F
Avoro Capital Advisors LLC 7.08% DEF14A
Vanguard Portfolio Management 5.79% 13G
State Street 5.57% 13F
Christopher Anzalone 3.00% DEF14A
FMR (Fidelity) 2.64% 13F
Morgan Stanley 1.47% 13F
Goldman Sachs 1.39% 13F
Norges Bank 1.33% 13F

Percentages above are of 125,572,000 shares outstanding, as reported by ARROWHEAD PHARMACEUTICALS INC. on its Form 10-Q dated December 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARROWHEAD PHARMACEUTICALS INC.’s 10-Q dated December 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At ARROWHEAD PHARMACEUTICALS INC.'s shareholder meeting held March 12, 2025, in the 2024-2025 proxy season, 277 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,480 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ARROWHEAD PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Advisory vote to approve named executive officer compensation. — the reporting funds and managers cast 94% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

ARROWHEAD PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.